RISK-BENEFIT ANALYSIS OF THERAPY IN MULTIPLE SCLEROSIS

被引：1
|
作者：
Qizilbash, N. [1 ]
Mendez, I [2 ]
Sanchez-de la Rosa, R. [3 ]
机构：
[1] Oxon Epidemiol Ltd, London, England
[2] Oxon Epidemiol Ltd, Madrid, Spain
[3] TEVA Pharma SLU, Madrid, Spain
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 07期
关键词：
D O I：
10.1016/j.jval.2011.08.469
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A317 / A318
页数：2
相关论文
共 50 条
  • [21] Symmetrical analysis of risk-benefit
    Warren, John B.
    Day, Simon
    Feldschreiber, Peter
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 74 (05) : 757 - 761
  • [22] A risk-benefit analysis of pioglitazone
    [J]. Reactions Weekly, 2014, 1483 (1) : 2 - 2
  • [23] RISK-BENEFIT PROFILES OF ANTIARRHYTHMIC THERAPY
    CAMPBELL, RWF
    NIMKHEDKAR, K
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1989, 64 (20): : J50 - J52
  • [24] Risk-benefit analysis of micronutrients
    Renwick, AG
    Flynn, A
    Fletcher, RJ
    Müller, DJG
    Tuijtelaars, S
    Verhagen, H
    [J]. FOOD AND CHEMICAL TOXICOLOGY, 2004, 42 (12) : 1903 - 1922
  • [25] EXAMPLES IN RISK-BENEFIT ANALYSIS
    WILSON, R
    [J]. CHEMTECH, 1975, 5 (10) : 604 - 607
  • [26] A RISK-BENEFIT ANALYSIS OF NATALIZUMAB ACROSS PML RISK SUB-GROUPS IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Walker, A. R.
    Deniz, B.
    Alexopoulos, S. T.
    Arnold, R.
    Bates, D.
    [J]. VALUE IN HEALTH, 2012, 15 (04) : A140 - A141
  • [27] RISK-BENEFIT ANALYSIS AND THE DETERMINATION OF ACCEPTABLE RISK
    DARDIS, R
    DAVENPORT, G
    KURIN, J
    MARR, J
    [J]. JOURNAL OF CONSUMER AFFAIRS, 1983, 17 (01) : 38 - 56
  • [28] A NOVEL ALGORITHM FOR ANALYSIS OF MULTIPLE ENDPOINTS USING RISK-BENEFIT PROFILES
    Gouskova, Natalia
    Kim, Dae
    Shi, Sandra
    Travison, Thomas
    [J]. INNOVATION IN AGING, 2021, 5 : 813 - 813
  • [29] RISK-BENEFIT
    MCCLUNG, N
    [J]. JOURNAL OF AUTISM AND CHILDHOOD SCHIZOPHRENIA, 1978, 8 (01): : 107 - 108
  • [30] RISK-BENEFIT
    MARTIN, J
    [J]. JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION, 1979, 174 (07) : 691 - 691
12345